liver transplant recipient (including organ transplant from a brain-dead donor)
Conditions
Interventions
daikenchuto group 5g of daikenchuto was administered orally three times a day from postoperative day 1 to 14.
placebo group 5g of placebo was administered orally three times a day from postoperative
Sponsors
Division of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Graduate School of medicine, Kyoto University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) patients who needs liver transplant. 2) adult patients who plans to undergo a liver transplant(including organ transplant from a brain-dead donor.) 3) Age >=20 at the time of registration. 4) patients who met the eligibility criteria of the recipient on the medical institution which performs liver transplant. 5) Informed consent on the form filled out by the patient or the legal representative of the person.
Exclusion criteria
Exclusion criteria: 1) patients with uncontrolled active infection , excluding infection in the liver and gall bladder 2) patients with uncontrolled cancer , excluding cancer in the liver 3) patients with the disease that cannot enforce a liver transplant safely 4) patients with the history of mechanical ileus , or assumed the intra-abdominal adhesion after gastrointestinal surgery. 5) patients taking prokinetic agent, antipsychotic drug, antidepressant, herbal medicine 6) females who are in pregnancy or lactation, may be pregnant 7) patients whom were considered inappropriate by the doctors for participation in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) intake of total calories in oral or enteral nutrition on postoperative day 7. 2) gastrointestinal symptoms on postoperative day 7. : NRS | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) intake of total calories in oral or enteral nutrition. 2) gastrointestinal symptoms: NRS 3) recovery of the gastrointestinal function after liver transplantation.(time to the first defecation.) 4) quality of life : GSRS score 5) assessment of liver function 6) rate of liver regeneration 7) rate of the bacteremia after liver transplantation 8) the trough of the immunosuppressive drug 9) acute cellular or humoral rejection. 10) the rate of leaving hospital on postoperative 2 months 11) portal venous blood flow 12) volume of ascites fluid 13) adverse event 14) adverse effect | — |
Countries
Japan
Contacts
Public ContactToshimi Kaido
Graduate School of medicine, Kyoto University Division of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery
Outcome results
None listed